Marinus Pharmaceuticals focuses on creating therapies aimed at improving the lives of individuals affected by seizure disorders. The company emphasizes innovation through cutting-edge science and collaborates with healthcare professionals to enhance patient care.
Marinus Pharmaceuticals Inc. ist ein Biotech, welcher sich auf Behandlungsmethoden von Epilepsie und neuropsychiatrischen Erkrankungen spezialisiert hat. Das Unternehmen entwickelt u.a. Ganaxolon für multiple Epilepsie und andere neuropsychiatrische Indikationen, einschließlich Zusatz- oder Add-on-Therapie zur Behandlung von arzneimittelresistenten fokalen Anfällen und pädiatrische PCDH19-Epilepsie....
Stockholm, April 10, 2025 – Immedica continues to expand its presence in the rare disease space by introducing a new Therapeutic Area (TA) and refining its existing structure....
Stockholm, Sweden – February 11, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, announced today the completion of the acquisition of...
Stockholm, Sweden – February 7, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, announced today that it has, through its indirect wholly...
Stockholm, Sweden – January 8, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, today announced that it will commence a tender offer...
